

Pharmapar Inc
Balance Sheet as at March 31, 2024

	Note No.	Amount in CAD	
		31-Mar-24	31-Mar-23
A ASSETS			
I Current assets			
(a) Inventories	1	-	422,803
(b) Financial assets			
Trade receivables	2	-	29,303
(c) Other Current Assets	3	-	190,000
Total current assets		-	642,106
 TOTAL ASSETS		-	642,106
 B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	4	5,000,397	5,000,397
(b) Reserves and Surplus	5	(8,277,156)	(7,511,835)
Total Equity		(3,276,759)	(2,511,438)
II Liabilities			
1 Non-current liabilities			
(a) Financial liabilities			
(i) Borrowings	6	2,525,621	2,479,178
Total non-current liabilities		2,525,621	2,479,178
2 Current liabilities			
(a) Financial liabilities			
(i) Trade payables	7	129,687	85,300
(ii) Other financial liabilities	8	434,923	402,537
(b) Provisions	9	186,528	186,529
Total current liabilities		751,138	674,366
 TOTAL EQUITY AND LIABILITIES		-	642,106

Pharmapar Inc
Statement of Profit And Loss for the Year Ended March 31, 2024

Particulars	Note No.	Amount in CAD	
		31-Mar-24	31-Mar-23
1 Revenue from operations		-	-
2 Other Income		-	-
3 Total Revenue (1+2)		-	-
4 Expenses			
(a) Cost of material consumed		-	-
(b) Employee benefits expense	10	15,000	15,000
(c) Finance costs	11	45,983	112,523
(d) Depreciation and amortisation expense		-	-
(e) Other expenses	12	62,232	160,565
Total expenses		123,215	288,088
5 Profit / (Loss) before exceptional items and taxes (3-4)		(123,215)	(288,088)
6 Exceptional Item	13	(642,106)	-
7 Profit / (Loss) before taxes (5+6)		(765,321)	(288,088)
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		(765,321)	(288,088)

Pharmapar Inc
Notes forming part of financial statement

Note No.

1 Inventories		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Stock In trade	-	422,803	
Total	-	422,803	

2 Trade receivables		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Unsecured			
Considered good	-	29,303	
Considered doubtful	-	67,789	
	-	97,092	
Less: Allowance for doubtful trade receivables	-	67,789	
Total	-	29,303	

3 Other current assets		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Unsecured, considered good			
Loans and advances to suppliers	-	190,000	
Total	-	190,000	

4 Share capital		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Issued, subscribed and fully paid-up			
Equity share capital	5,000,397	5,000,397	
Total	5,000,397	5,000,397	

5 Reserves and surplus		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Surplus in statement of profit and loss			
Opening balance	(7,511,835)	(7,223,747)	
Add: Profit / (Loss) for the year	(765,321)	(288,088)	
Closing balance	(8,277,156)	(7,511,835)	
Total	(8,277,156)	(7,511,835)	

6 Long term borrowings		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Loan from related Parties	2,525,621	2,479,178	
Total	2,525,621	2,479,178	

7 Trade payables		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Trade payable	129,687	85,300	
Total	129,687	85,300	

8 Other Current financial Liabilities		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Payable to group entities	434,923	402,537	
Total	434,923	402,537	

9 Provisions		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Provision for Taxation	186,528	186,529	
Total	186,528	186,529	

Pharmapar Inc
Notes forming part of financial statement

Note No.

10 Employee benefit expenses		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Salaries and wages	15,000	15,000	
Total	15,000	15,000	

11 Finance cost		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Bank charges	200	112,523	
Interest cost	45,783	-	
Total	45,983	112,523	

12 Other expenses		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Rates & taxes	56,232	145,714	
Communication expenses	1,000	1,000	
Membership fees and subscription	-	13,851	
Professional fees & Legal fees	5,000	-	
Total	62,232	160,565	

13 Exceptional items		Amount in CAD	
Particulars	31-Mar-24	31-Mar-23	
Impairment and write down of assets	(642,106)	-	
Total	(642,106)	-	